Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2020-11-01
2029-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Furthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor
NCT01511146
A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
NCT02395224
Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma
NCT02537743
Symptomatic and Incidental RCC Detection
NCT07004426
A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)
NCT05548621
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Treatment of metastatic renal cell carcinoma (mRCC) is ineffective among 25 % of patients. However, treatment still reduces patients' quality of life.
From clinical experience, interindividual dose requirements vary greatly among patients with mRCC treated with tyrosine kinase inhibitors.
The investigators expect this to partly be explained by great variation in the plasma concentration of treatment drugs. Furthermore, treatment failure among patients with mRCC treated with check point immunotherapy has not been fully investigated.
RATIONALE:
The few studies concerning plasma concentration measurement of tyrosine kinase inhibitors in patients with mRCC have found that a certain level of drug concentration is necessary for treatment efficacy. The role of plasma concentration in side effects is yet unknown.
Anti drug antibodies against the check point inhibitor ipilimumab has been shown to reduce efficacy and lead to treatment failure among patients with malignant melanoma. Receptor polymorphism in CTLA-4 and PD-1 receptors in terms of efficacy have not yet been studied.
A therapeutic drug interval for TKI treatment will allow for quicker and more precise dosing, and early signs of treatment failure of checkpoint immunotherapy will allow for quicker change of therapy, or define a subgroup of patients who will not benefit from checkpoint immunotherapy and therefore should be offered another effective treatment instead.
HYPOTHESIS:
1. Patients treated with TKIs for more than 6 months have an optimal plasma trough concentration (Cmin). Objective response rate, progression free survival (PFS), overall survival (OS), and toxicity in these patients are favorable compared with pivotal phase III study results.
2. We hypothesize that it is possible to elucidate a therapeutic interval for the TKIs examined in the study
3. Patients treated with CPI obtaining response have a higher plasma trough (Cmin) concentration value of ipilimumab and nivolumab than patients with progressive disease (PD). Patients treated with CPI who develop PD have a higher amount of ADA than patients with response to treatment.
4. Certain polymorphisms in CTLA-4 and PD-1 are associated with poor outcome.
5. UGT1A1 polymorphism is associated with improved survival despite dose reductions in patients treated with pazopanib.
6. The microbiome composition correlates with treatment outcome of CPI.
7. CT DNA measurement may be marker of disease activity and treatment effect.
MATERIALS AND METHODS:
All eligible TKI-patients will have blood samples drawn at each clinical visit during a 6-months period.
The plasma concentration of TKIs will be measured with liquid chromatography-mass spectrometry at the Department of Clinical Biochemistry at Aarhus University Hospital.
All eligible CPI-patients will have blood samples drawn and fecal swap performed from start CPI-treatment and during treatment until treatment failure or full treatment (2 years).
Analysis of blood and microbiome from patients receiving checkpoint immunotherapy will be be done using in-house bead-based assays, anti-human IgG detection antibody and in-house developed flow cytometry-based assay at the Institute for Inflammation Research at Rigshospitalet.
TKI STUDY AIM:
To compare the trough plasma concentrations (Cmin) of TKIs in patients with mRCC having stable disease with those experiencing toxicity, treatment failure, and stable disease or regression, respectively to identify the optimal plasma concentration level.
CPI STUDY AIMS:
Aim 1: To compare the trough plasma concentration of CPI with toxicity and outcome in patients with mRCC to identify the optimal plasma concentration level.
Aim 2: To measure the concentration of circulating ADA against immune-checkpoint inhibitors ipilimumab and nivolumab in patients with mRCC and correlate best objective response to the concentration of ADA.
Aim 3: To compare polymorphisms in CTLA-4 and PD-1 and correlate findings with clinical outcomes in patients with mRCC treated with ipilimumab and/or nivolumab.
Aim 4: To delineate the microbiome in mRCC patients treated with immunotherapy and associating it to response and survival.
Aim 5: To use circulating tumor DNA as a marker for disease activity and treatment effect in mRCC patients.
Overall survival, progression free survival and quality of life using FKSI-19 questionnaire will be recorded for each patient.
This is an observational study among Danish patients treated for mRCC over a 7 year year period.
Perspectives of TDM in TKI patients:
Determining a therapeutic interval for TKIs could optimize treatment for mRCC patients by:
1. Titrating up doses for patients with insufficient levels to reduce cancer progression risk.
2. Titrating down doses for overdosed patients to limit toxicity and costs.
3. Monitoring patients on intermittent therapy interacting with TKI treatment. These results may extend to other cancer types using TKIs.
Perspectives for TDM in CPI patients:
A therapeutic interval and characterisation of treatment failure of CPI will most likely optimize treatment for patients with mRCC for the following reasons:
1. Patients who receive an insufficient dose and therefore have a potential risk of cancer progression can be titrated up to a sufficient level.
2. Patients who develop serious adverse events are overdosed and can be titrated down to a sufficient level - limiting toxicity and cost.
3. Patients who develop ADAs or have insufficient binding between CPI and T-lymphocytes can switch to another effective therapy before cancer progression.
These results will likely extrapolate to other cancer types as CPI is increasingly being used for other cancer diagnoses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Patients treated for metastatic renal cell carcinoma in Denmark over a 6-year period.
Measurement of concentration of active metabolite in cancer treatment.
Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib and ipilimumab and nivolumab.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measurement of concentration of active metabolite in cancer treatment.
Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib and ipilimumab and nivolumab.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Herlev Hospital
OTHER
Rigshospitalet, Denmark
OTHER
Niels Fristrup
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Niels Fristrup
MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Niels Fristrup, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Aarhus
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Oncology, Aarhus University Hospital
Aarhus, Danmark, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Henriksen JN, Andersen CU, Donskov F, Hoffmann-Lucke E, Greibe E, Fristrup N. Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol. Acta Oncol. 2025 Jun 2;64:729-733. doi: 10.2340/1651-226X.2025.43693.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TDM mRCC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.